6.20 USD
▲-0.08+7.27%
盘后 5.64 -2.42%
2026-08-03
市值
$1.98B
市盈率
—
EPS
-0.38
股息率
—
52 周区间
2.54 – 7.30
成交量
3.70M
Beta
1.16
目标价
13.15
52W 低 2.5452W 高 7.30
价格走势
公司简介
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-...